Clinical Trials Logo

Renal Artery Stenosis clinical trials

View clinical trials related to Renal Artery Stenosis.

Filter by:

NCT ID: NCT05612438 Not yet recruiting - Renal Failure Clinical Trials

RADIX 2 RENAL STENT Post-Market Retrospective Study

RADIX 2
Start date: March 3, 2023
Phase:
Study type: Observational

The Carbostentâ„¢ Radix 2 stent is a CE marked balloon expandable bare metal stent for the treatment of renal artery stenosis. The aim of this post-market retrospective study protocol P12204, is to collect clinical data on patients treated with the RADIX 2 stent in routine clinical practice. In order to obtain long-term follow-up data, the data collection will be limited to patients that have been treated with the Radix 2 stent at least 12 months prior to the study start.

NCT ID: NCT05603221 Recruiting - Clinical trials for Renal Artery Stenosis

Renal Perfusion Assessment in the Endovascular Treatment of Renal Artery Stenosis

Start date: November 4, 2020
Phase:
Study type: Observational

The clinical benefits of endovascular treatment in renal artery stenosis remain controversial. This study uses arterial spin labelling MRI and flat-panel detector parenchymal blood volume imaging to observe the change in renal perfusion after endovascular treatment in renal artery stenosis.

NCT ID: NCT04423458 Completed - Clinical trials for Chronic Kidney Diseases

Evaluation of Advanced US Tools in Assessing Allograft Complications

Start date: January 4, 2022
Phase:
Study type: Observational

This study evaluates the role of advanced US technology in assessing renal transplants as screening tools such as 3D Ultrasound, Ultrasound SWE, and MFI besides current ultrasound conventional metheds.

NCT ID: NCT03914157 Withdrawn - Clinical trials for Renal Artery Stenosis

Ultrasound Wave Therapy for Post-stenotic Microvascular Remodeling

Start date: March 2023
Phase: N/A
Study type: Interventional

Researchers are evaluating a noninvasive treatment with ultrasound waves for Atherosclerotic Renal Artery Stenosis (ARAS).

NCT ID: NCT03594786 Recruiting - Clinical trials for Aortic Aneurysm, Abdominal

Impact of Supra-renal Fixation of EVAR on Hemodynamics of Renal Arteries

IFIXEAR
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

The investigators conducted a bicentric prospective study to quantify the hemodynamic disturbances to the ostia of the renal arteries generated by the implantation EVAR with suprarenal fixation immediately postoperatively.

NCT ID: NCT03530748 Recruiting - Aortic Dissection Clinical Trials

On-table Renal Perfusion Evaluation Renal Artery Stenosis or Obstruction

Start date: April 9, 2018
Phase:
Study type: Observational

1. Evaluate the feasibility for the on-table evaluation of the renal perfusion by using Syngo Dyna Parenchymal Blood Volume(PBV) Body; 2. Explore the clinical benefits of this application during procedure to help the physician to determine the procedure endpoint.

NCT ID: NCT03382301 Completed - Clinical trials for Renal Artery Stenosis

Ciclosporin A Preconditioning for Renal Artery Stenosis

CicloSAAR
Start date: August 28, 2018
Phase: Phase 2
Study type: Interventional

Renal artery stenosis is one the leading cause of secondary hypertension. Previous randomized controlled trials in humans have failed to demonstrate an improvement of renal function after stenosis dilation, probably because of a selection bias with more severe patients being excluded from randomization. Renal ischemia-reperfusion injuries have also not been taken into account. Indeed, reperfusion leads to a rapid renal blood flow recovery associated with renal ischemia-reperfusion injuries. Mitochondrial permeability transition pore (mPTP) is a key player in the occurrence of ischemia reperfusion injuries because its opening leads to mitochondria leakage and cell death. However, preconditioning whether pharmacological or ischemic can prevent mPTP opening and protect cells. Ciclosporin A can prolong mPTP closing during reperfusion and reduce renal and cardiac tissular lesions. Another mPTP blocker (Bendavia) has been associated with an improvement of renal blood flow (RBF) and glomerular filtration rate (GFR) after renal artery stenosis dilation at 6 weeks in pigs. Based on a recent study, dilation overall benefit could be secondary to an improvement of the contralateral kidney GFR and tissue oxygen content, requiring a single kidney evaluation of those renal functional parameters. The investigators previously demonstrated that dose and timing of ciclosporin A preconditioning is key to protect kidneys from ischemia-reperfusion injuries. Previous controlled trials that failed to demonstrate a benefit of ciclosporin A conditioning have used post conditioning on necrotic cells. Considering kidney ischemia-reperfusion injuries, preconditioning have led to more encouraging results compared to ciclosporin A post conditioning in animals. Therefore the investigators aim to conduct the first clinical study of ciclosporin A preconditioning for prevention of kidney ischemia-reperfusion injuries after renal artery stenosis dilation. Using renal functional imaging and the new PET-MRI (Positron Emission Tomography-Magnetic Resonance Imaging) combined device, the investigators will evaluate kidney perfusion, oxidative metabolism, glomerular filtration rate and oxygen content before and 3 months after renal artery stenosis dilation with or without a ciclosporin A preconditioning.

NCT ID: NCT03252639 Recruiting - Clinical trials for Renal Artery Stenosis

A Study of Using Parenchymal Blood Volume(PBV) for Endovascular Treatment of Renal Arterial Stenosis

Start date: November 2016
Phase: N/A
Study type: Observational

This study will use PBV technique to quantitatively assess the improvement of renal perfusion before and after endovascular treatment (EVT) of renal artery stenosis.

NCT ID: NCT02655341 Recruiting - Clinical trials for Acute Myocardial Infarction

Hydration Status Assessment Through Body Composition Monitoring in Patients With Acute Myocardial Infarction

HYD-AMI
Start date: January 2016
Phase: N/A
Study type: Observational

Aims: - evaluate the hydric status through bioimpedance spectroscopy in consecutive acute myocardial infarction patients referred for primary PCI; - assessment of renal artery stenosis incidence through renal angiography in consecutive STEMI patients; - fully characterize the complex hydration, metabolic and endothelial profile of these patients in the attempt to define the role played by dehydration in the complex dynamics of acute myocardial infarction.

NCT ID: NCT02528149 Completed - Clinical trials for Renal Artery Stenosis

Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study

Start date: September 2013
Phase: N/A
Study type: Observational

Fibromuscular dysplasia (FMD) is localized structural defects in the arterial wall, whose innate or acquired character is still unknown. This segmental non atheromatous injury, leads to stenosis of the arteries of small and medium caliber. Renal arteries are the most commonly affected with 60-75% of total fibrodysplasia. Three histological subtypes have been described: intimal, medial and peri-medial. They are not mutually exclusive and can be observed in the same patient. This is a rare blood disease, occurring in children and young adults. In this young population with long life expectancy, these aneurysmal lesion are associated with 10% risk of rupture. To date, no data have shown in the literature that FMD is link to genetic causes, or if there is specific histopathologic lesions for non-atherosclerotic renal artery aneurysms. To answer these questions, Cardiovascular Surgery Unit of the University Hospital of Saint-Etienne, French national reference center for renal artery surgery, in association with the Reference Center for Rare Vascular Disease in Paris, designed the first study for pathological and genetic characteristics of dysplastic renal artery aneurysms in young patients.